Fetal lung surfactant and development alterations in intrahepatic cholestasis of pregnancy

Table 1 Variable characteristics between intrahepatic cholestasis of pregnancy and the control group

	Control (n = 32)	Intrahepatic cholestasis of pregnancy (n = 40)
Total bile acid (mmol/L)
Maternal serum	4.55 ± 1.72	34.11 ± 6.75a
Umbilical artery serum	3.52 ± 1.56	11.9 ± 2.23a
Amniotic fluid	1.43 ± 1.14	3.89 ± 1.99a
Amniotic fluid phospholipids
PC (μg/mL)	69.70 ± 6.68	65.71 ± 7.23a
PI (μg/mL)	4.28 ± 0.74	3.87 ± 0.65a
LPC (μg/mL)	4.21 ± 0.64	4.72 ± 0.86a
SM (μg/mL)	3.95 ± 0.53	3.63 ± 0.66
PC/LPC (μg/mL)	6.90 ± 2.52	14.40 ± 3.14a
Lamellar body (× 109/L)	103.0 ± 26.82	74.13 ± 4.37a
Perinatal outcomes
Fetal distress	4 (12.4)	13 (32.5)
Neonatal asphyxia	1 (3.13)	2 (5)
NRDS	2 (6.25)	6 (15)
Perinatal death	0	1 (2.5)

Data are expressed as absolute mean ± SD or numbers (percentage). PC: Phosphatidylcholine; PI: Phosphatidylinositol; LPC: Lysolecithin; SM: Sphingomyelin; NRDS: Neonatal respiratory distress syndrome.

^aP < 0.05 vs control group.